Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases

• US 20050153989A1
• Filed: 01/13/2005
• Published: 07/14/2005
• Est. Priority Date: 01/13/2004
• Status: Abandoned Application

• Current Assignee: Ambit Biosciences Corporation (Daiichi Sankyo Company Limited)
• Original Assignee: Ambit Biosciences Corporation (Daiichi Sankyo Company Limited)
• Inventors: Patel, Hitesh K., Lockhart, David J., Lai, Andiliy G., Milanov, Zdravko V., Mehta, Shamal A., Grotzfeld, Robert M.
• Application Number:
  US11/036,241
• Publication Number:
  US 20050153989A1
• Time in Patent Office: Days
• US Class Current: 514/260.100
• CPC Class Codes: A61K 31/519 ortho- or peri-condensed with heterocyclic rings
• CPC Class Codes: A61K 31/52 Purines, e.g. adenine
• CPC Class Codes: A61K 31/522 having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• CPC Class Codes: C07D 487/04 Ortho-condensed systems
• CPC Class Codes: C07D 491/04 Ortho-condensed systems
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Described herein are compounds and compositions for modulating kinase activity, and methods for modulating kinase activity using the compounds and compositions. Also described herein are methods of using the compounds and/or compositions in the treatment and prevention of a variety of diseases and unwanted conditions in subjects.

Claims

1. A method for treating a disease comprising administering to a subject in need thereof an effective amount of an epidermal growth factor receptor modulating corresponding to Formula (I):

2. The method of claim 1, wherein R₁ of said compound is

3. The method of claim 1, wherein R₅ of said compound is H or

4. The method of claim 1, wherein X₁ of said compound is CR₆ and X₂ of said compound is NR₄.

5. The method of claim 1, wherein said compound corresponds to Formula (Ia):

6. The method of claim 1, wherein said compound corresponds to Formula (Ib):

7. The method of claim 1, wherein said compound corresponds to Formula (IIa):

8. The method of claim 1, wherein said compound corresponds to Formula (lIb):

9. The method of claim 1, wherein said compound corresponds to Formula (IIa):

10. The method of claim 1, wherein said compound corresponds to Formula (IIIa):

11. The method of claim 1, wherein said compound corresponds to Formula (A1):

12. The method of claim 1, wherein said compound corresponds to Formula (A2):

13. The method of claim 12, wherein said compound corresponds to Formula (B2):

14. The method of claim 12, wherein said compound corresponds to Formula (C2):

15. The method of claim 1, wherein said compound corresponds to Formula (D2):

17. The method of claim 1, wherein said compound corresponds to Formula (IV):

18. The method of claim 17, wherein said compound corresponds to Formula (N2):

19. The method of claim 18, wherein said compound corresponds to Formula (N3):

20. The method of claim 19, wherein said compound corresponds to Formula (N4):

16. The compound of claim 16, corresponding to Formula (E2):

21. A method for modulating epidermal growth factor receptor (EGFR) activity comprising contacting EGFR with an effective amount of an EGFR modulating compound corresponding to Formula (I):

22. The method of claim 21, wherein the contacting occurs within a human patient, wherein the human patient has an EGFR-mediated disease or condition.

23. The method of claim 22, wherein the effective amount is an amount effective for treating an EGFR-mediated disease or condition within the body of the person.

24. The method of claim 23 wherein the EGFR-mediated disease or condition is selected from the group consisting of blood vessel growth, cancer, benign hyperplasia, keloid formation, and psoriasis.

25. A method for treating a disease comprising administering to a subject in need thereof an effective amount of an epidermal growth factor receptor modulating corresponding to:

26. The method of claim 25, wherein the disease is selected from the group consisting of blood vessel growth, cancer, benign hyperplasia, keloid formation, and psoriasis.